SPC410
Berótralstat eða lyfjafræðilega viðunandi sölt þar af
Status:
UmsóknApplication date:
17.11.2022Application published:
15.12.2022
Max expiry date:
29.4.2036Medicine name:
OrladeyoMedicine for children:
No
Timeline
Today
17.11.2022Application
15.12.2022Publication
29.4.2036Expires
Marketing license
IS authorization number:
EU/1/21/1544/001-002Date:
14.5.2021
Foreign authorization number:
EU/1/21/1544Date:
30.4.2022
Owner
Name:
BioCryst Pharmaceuticals, Inc.Address:
4505 Emperor Blvd., Durham, NC 27703 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP3828173